6533b86efe1ef96bd12cbce6
RESEARCH PRODUCT
Effects of the prostanoid EP3 -receptor agonists M&B 28767 and GR 63799X on infarct size caused by regional myocardial ischaemia in the anaesthetized rat
Gerd HafnerChristoph ThiemermannKai ZacharowskiAntje OlbrichMike Ottosubject
PharmacologyCardioprotectionTroponin Tbusiness.industryProstanoidPharmacologyPotassium channelGlibenclamidechemistry.chemical_compoundChelerythrinechemistryAnesthesiamedicineStaurosporinebusinessProtein kinase Cmedicine.drugdescription
1. This study investigates the effects of two agonists of the prostanoid EP3-receptor (MB PEEP: 1-2 mmHg) and subjected to occlusion of the left anterior descending coronary artery (LAD, for 7.5, 15, 25, 35, 45 or 60 min) followed by reperfusion (2 h). Infarct size was determined by staining of viable myocardium with a tetrazolium stain (NBT), histological evaluation by light and electron microscopy and determination of the plasma levels of cardiac troponin T. 3. MB saline-control, n=8) to 39+/-6 and 38+/-4% of the area at risk, without causing a significant fall in blood pressure. Pretreatment of rats with 5-hydroxydecanoate (5-HD), an inhibitor of ATP-sensitive potassium channels, attenuated the cardioprotective effects of both EP3-receptor agonists. The reduction in infarct size afforded by M&B 28767 was also abolished by glibenclamide and the protein kinase C (PKC) inhibitors staurosporine and chelerythrine. 4. Thus, M&B 28767 and GR 63799X reduce myocardial infarct size in the rat by a mechanism(s) which involves the activation of PKC and the opening of ATP-sensitive potassium channels.
year | journal | country | edition | language |
---|---|---|---|---|
1999-02-01 | British Journal of Pharmacology |